Table 1.
Patients' characteristics.
| Baseline characteristics (n = 178)A | |||
|---|---|---|---|
| Age—median years (Q1–Q3) | 59 (43–71) | Anticoagulation—N (%) | 46 (26%) |
| Male gender—N (%) | 121 (68%) | Platelet inhibitors—N (%) | 57 (32%) |
| BMI—median (Q1–Q3) | 25 (22–25) | Co-morbidities—N (%) | |
| ICU admission—N (%) | 46 (26%) | Hypertension | 102 (57%) |
| 28 day mortality—N (%) | 29 (16%) | Heart disease | 75 (42%) |
| Adequate antimicrobial treatmentB–N (%) | 163 (92%) | Renal impairment | 59 (33%) |
| Time to positivity—median hours (Q1–Q3) | 11 (6–16) | Diabetes | 41 (23%) |
| MRSA—N (%) | 13 (7%) | Malignancy | 34 (19%) |
| Genetic markers—N (%) | Hypothyroidism | 28 (16%) | |
| fnbA | 148 (83%) | Liver cirrhosis | 28 (16%) |
| fnbB | 40 (22%) | COPD | 17 (10%) |
| clfA | 174 (98%) | Autoimmune disease | 16 (9%) |
| clfB | 173 (97%) | i.v. drug abuse | 14 (8%) |
| fib | 84 (47%) | Leukemia | 10 (6%) |
| Vwbp | 170 (96%) | Solid-organ transplant | 10 (6%) |
| Infection focus (ECDC)C–N (%) | Laboratory parameters -median (Q1–Q3) | ||
| Unknown source | 86 (48%) | CRP (mg/dL) | 12 (6–23) |
| Catheter-related | 31 (17%) | White blood cell count (G/L) | 9.9 (6.6–13.7) |
| Pulmonary infection | 18 (10%) | Platelets (G/L) | 159 (106–248) |
| Surgical site infection | 9 (5%) | Hemoglobin (g/dL) | 10.4 (9.2–12) |
| Endocarditis | 6 (3%) | Creatinine (mg/dL) | 1.1 (0.8–1.9) |
| Bone infection | 5 (3%) | Blood urea nitrogen (mg/dL) | 21.3 (14.3–21.2) |
| Joint infection | 5 (3%) | Fibrinogen (mg/dL) | 493 (359–633) |
| Urinary tract infection | 5 (3%) | Prothrombin time (%) | 72 (49–89) |
| Digestive tract infection | 2 (1%) | Albumin (g/L) | 30.5 (26.5–36.8) |
| Total Bilirubin (mg/dL) | 0.7 (0.5–1.4) | ||
BMI, Body Mass Index, ICU, Intensive care unit; MRSA, Methicillin-resistant Staphylococcus aureus; COPD, chronic obstructive pulmonary disease; coa, coagulase; vWbp, von Willebrand factor-binding protein; clfA and clfB, clumping factor A and B; fnbA and fnbB, fibronectin-binding protein A and B; fib, fibrinogen-binding protein; ECDC, European Center of Disease Control; CRP, C-reactive protein.
Q1–Q3: Quartile 1 to Quartile 3.
Adequate antimircobial treatment: defined as the initiation of at least one antimicrobial substance to which the isolated strain showed in vitro susceptibility according to the clinical breakpoints of the European Committee on Antimicrobial Susceptibility Testing (The European Committee on Antimicrobial Susceptibility Testing. Breakpoint tables for interpretation of MICs and zone diameters. Version 9.0, 2019) (EUCAST).
European Centre for Disease Prevention and Control (ECDC) point prevalence survey of healthcare-associated infections (European Centre for Disease Prevention Control, 2015).